To access the full text documents, please follow this link: http://hdl.handle.net/2445/128127

Molecular liver cancer prevention in cirrhosis by organ transcriptome analysis and lysophosphatidic acid pathway inhibition
Nakagawa, Shigeki; Wei, Lan; Song, Won Min; Higashi, Takaaki; Ghoshal, Sarani; Kim, Rosa S.; Bian, C. Billie; Yamada, Suguru; Sun, Xiaochen; Venkatesh, Anu; Goossens, Nicolas; Bain, Gretchen; Lauwers, Gregory Y.; Koh, A. P.; El-Abtah, Mohamed; Ahmad, Noor B.; Hoshida, Hiroki; Erstad, Derek J.; Gunasekaran, Ganesh; Lee, Youngmin; Yu, Ming-Lung; Chuang, Wan-Long; Dai, Chia-Yen; Kobayashi, Masahiro; Kumada, Hiromitsu; Beppu, Toru; Baba, Hideo; Mahajan, Milind; Nair, Venugopalan D.; Lanuti, Michael; Villanueva, Augusto; Sangiovanni, Angelo; Iavarone, Massimo; Colombo, Massimo; Llovet i Bayer, Josep Maria; Subramanian, Aravind; Tager, Andrew M.; Friedman, Scott L.; Baumert, Thomas F.; Schwartz, Myron; Chung, Raymond T.; Tanabe, Kenneth K.; Zhang, Bin; Fuchs, Bryan C.; Hoshida, Yujin; Precision Liver Cancer Prevention Consortium
Cirrhosis is a milieu that develops hepatocellular carcinoma (HCC), the second most lethal cancer worldwide. HCC prediction and prevention in cirrhosis are key unmet medical needs. Here we have established an HCC risk gene signature applicable to all major HCC etiologies: hepatitis B/C, alcohol, and non-alcoholic steatohepatitis. A transcriptome meta-analysis of >500 human cirrhotics revealed global regulatory gene modules driving HCC risk and the lysophosphatidic acid pathway as a central chemoprevention target. Pharmacological inhibition of the pathway in vivo reduced tumors and reversed the gene signature, which was verified in organotypic ex vivo culture of patient-derived fibrotic liver tissues. These results demonstrate the utility of clinical organ transcriptome to enable a strategy, namely, reverse-engineering precision cancer prevention.
-Càncer de fetge
-Cirrosi hepàtica
-Liver cancer
-Hepatic cirrhosis
cc-by-nc-nd (c) Elsevier, 2016
http://creativecommons.org/licenses/by-nc-nd/3.0/es
Article
Article - Accepted version
Elsevier
         

Show full item record

Related documents

Other documents of the same author

Nakagawa, Shigeki; Wei, Lan; Song, Won Min; Higashi, Takaaki; Ghoshal, Sarani; Kim, Rosa S.; Bian, C. Billie; Yamada, Suguru; Sun, Xiaochen; Venkatesh, Anu; Goossens, Nicolas; Bain, Gretchen; Lauwers, Gregory Y.; Koh, A. P.; El-Abtah, Mohamed; Ahmad, Noor B.; Hoshida, Hiroki; Erstad, Derek J.; Gunasekaran, Ganesh; Lee, Youngmin; Yu, Ming-Lung; Chuang, Wan-Long; Dai, Chia-Yen; Kobayashi, Masahiro; Kumada, Hiromitsu; Beppu, Toru; Baba, Hideo; Mahajan, Milind; Nair, Venugopalan D.; Lanuti, Michael; Villanueva, Augusto; Sangiovanni, Angelo; Iavarone, Massimo; Colombo, Massimo; Llovet i Bayer, Josep Maria; Subramanian, Aravind; Tager, Andrew M.; Friedman, Scott L.; Baumert, Thomas F.; Schwartz, Myron E.; Chung, Raymond T.; Tanabe, Kenneth K.; Zhang, Bin; Fuchs, Bryan C.; Hoshida, Yujin; Precision Liver Cancer Prevention Consortium
 

Coordination

 

Supporters